Boston Pharmaceuticals Announces COO Appointment

Boston Pharmaceuticals announced the appointment of Joanne Beck, Ph.D., as Chief Operating Officer.

Dr. Beck joins Boston Pharmaceuticals from Celgene Corporation, where she was Executive Vice President of Global Pharmaceutical Development and Operations and led the Celgene’s pharmaceutical, biologics and cell therapy technical development, global supply chain and quality operations. At Boston Pharmaceuticals, Dr. Beck will provide leadership and oversight of development strategy and cross-functional operations.

"We are thrilled to welcome Joanne to the leadership team as we transition toward the next stage of growth," said Robert Armstrong, PhD, Chief Executive Officer & Co-Founder of Boston Pharmaceuticals. "Joanne brings over a decade of experience in pharmaceutical process development and clinical manufacturing across a broad range of therapeutic areas. Her deep expertise in global pharmaceutical operations is a tremendous asset to Boston Pharmaceuticals and will be instrumental in building on our pipeline and success."

"Boston Pharmaceuticals has made tremendous progress in the past few years and its growth has been acknowledged by the industry," said Dr. Beck. "I am impressed with the company’s unique strategy of selecting high-value candidates and advancing them through the next appropriate value inflection point. I look forward to leveraging my experience to support the company’s growth at this pivotal time as it continues to advance a diversified portfolio of candidates through the clinic."

Prior to Celgene, Dr. Beck served as Senior Vice President of Pharmaceutical Development at Shire where she was responsible for CMC development and clinical manufacturing and led the advancement of a diverse product portfolio which included small molecules, proteins, mAbs, Gene Therapy and mRNA therapeutics. Prior to joining Shire, she held leadership positions in Abbott’s Global Pharmaceutical Operations and Abbott Vascular and led. Prior to Abbott, she held positions of increasing responsibility at Genentech’s and Amgen’s Process Development organizations. She holds a Ph.D. in Biochemistry and Molecular Biology from the Oregon Health and Sciences University, a B.A. in Chemistry from Lewis and Clark College and completed Postdoctoral Fellowships at the University of California San Francisco and at Genentech Inc. Dr. Beck serves on the board of directors for Orchard Therapeutics and Catabasis Pharmaceuticals.

Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the reproduced articles,

please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.